Metaba is a privately held preclinical biopharmaceutical company leveraging innovative, hypothesis-driven strategies to develop life-saving therapies for infectious diseases. Originally founded to create an adjunctive therapeutic for Tuberculosis (TB), we quickly expanded through collaborations and successful pilot projects with leading global pharmaceutical companies and research institutions to combat other critical conditions. Among these, we have identified semi-synthetic, orally bioavailable, oxysterol-based compounds with bactericidal activity against drug-resistant Mycobacterium tuberculosis (Mtb). We are developing these compounds to target not only Mtb but also other bacteria, aiming to address the growing global health crisis of antimicrobial resistance by advancing first-in-class, more efficacious, and safer antibiotic solutions.